Generic Claritin Does Not Infringe Schering Patent - Appeals Court
This article was originally published in The Tan Sheet
Executive Summary
The Aug. 1 decision by a Washington D.C. federal appeals court finding certain loratadine patent claims invalid "does not preclude patent protection for metabolites of known drugs," the judges write
You may also be interested in...
Claritin Litigation Rehearing Denial Could Affect New Drug Patents
A Washington, D.C. federal appeals court ruling not to rehear Schering-Plough's adverse desloratadine patent infringement decision en banc could hold serious implications for future new drugs and biologics, two dissenting judges argue
Leiner ships loratadine
Private label manufacturer to launch loratadine 10 mg tablets to retailers including Wal-Mart, CVS and BJs by the end of August, firm rep says Aug. 5. Leiner expects the loratadine product will retail for between 10-40¢ per pill. Schering-Plough's Claritin currently costs around 60¢ per loratadine 10 mg tablet at CVS. An Aug. 1 U.S. Court of Appeals ruling against Schering finding certain loratadine patent claims invalid allowed Leiner to commence marketing its private label loratadine version (1"The Tan Sheet" Aug. 4, 2003, p. 3)...
Desloratadine Patent Claims No Bar To Generic Claritin, Judge Says
Schering-Plough will not be able to rely on patent claims covering desloratadine to keep generic versions of its Claritin antihistamine off the OTC market before 2004 if a federal judge's ruling is upheld on appeal